Innate Pharma (IPHA) Set to Announce Quarterly Earnings on Wednesday

Innate Pharma (NASDAQ:IPHA) is scheduled to be releasing its earnings data before the market opens on Wednesday, November 13th.

Innate Pharma Stock Down 10.5 %

Shares of IPHA stock opened at $1.84 on Friday. The firm’s fifty day simple moving average is $2.10 and its 200 day simple moving average is $2.27. Innate Pharma has a 1 year low of $1.70 and a 1 year high of $3.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IPHA shares. HC Wainwright reissued a “buy” rating and set a $11.50 target price on shares of Innate Pharma in a research report on Friday, September 13th. Evercore ISI upgraded Innate Pharma to a “strong-buy” rating in a research report on Monday, September 16th.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.